American Academy of Otolaryngology–Head and Neck Surgery

OM1 Launches Asthma and Chronic Rhinosinusitis Datasets to Expand Real-World Evidence in Respiratory and ENT

Retrieved on: 
Monday, October 2, 2023
Technology, Health Technology, Networks, Other Health, Managed Care, Health, General Health, Data Management, Artificial Intelligence, Partnership, OM1, AAO, Classification, CRS, American Academy of Otolaryngology–Head and Neck Surgery, Sinusitis, American Academy, Polyp (medicine), Patient, Annual general meeting, Otorhinolaryngology, Conditional sentence, AI, Disease, Pharmaceutical industry, Asthma

OM1 , a leading real-world data, AI, and technology company with a focus on chronic diseases, announced the launch of two new clinical datasets, Chronic Rhinosinusitis (CRS) and Asthma .

Key Points: 
  • OM1 , a leading real-world data, AI, and technology company with a focus on chronic diseases, announced the launch of two new clinical datasets, Chronic Rhinosinusitis (CRS) and Asthma .
  • Rapidly growing, the CRS and Asthma datasets each follow approximately 500,000 patients in the U.S.
  • The research-grade, real-world data available in the OM1 Respiratory & ENT Network is built with an exclusive partnership between OM1 and the American Academy of Otolaryngology and Head and Neck Surgery Foundation (AAO-HNSF).
  • Millions of Americans are impacted by respiratory diseases, and the number continues to rise as respiratory illnesses become more common and air quality declines.

Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings

Retrieved on: 
Thursday, September 28, 2023
Biotechnology, Other Health, Health, General Health, Oncology, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, TTMV, Abstract, DNA, Session, San Diego Convention Center, Head, ASTRO, OPSCC, Booth, Cancer, American Academy of Otolaryngology–Head and Neck Surgery, American Academy, Radiation therapy, American Society for Radiation Oncology, MRD, MD, Annual general meeting, HPV, AM, Neoplasm, Recurrence, Society, Neck, Vaccine, Raoul de Navery

Naveris will be exhibiting at both meetings, providing the latest information on NavDx®, Naveris’ proprietary flagship blood test for tumor tissue modified viral (TTMV®)-HPV DNA.

Key Points: 
  • Naveris will be exhibiting at both meetings, providing the latest information on NavDx®, Naveris’ proprietary flagship blood test for tumor tissue modified viral (TTMV®)-HPV DNA.
  • The company will also highlight its TTMV-DNA platform in abstracts selected for oral presentation at both meetings.
  • “There is growing enthusiasm for the use of NavDx in daily practice across the continuum of HPV-driven OPSCC care, especially in the surveillance setting,” said Barry M. Berger, MD, Chief Medical Officer of Naveris.
  • Naveris and NavDx will be on exhibit at AAO-HNSF 2023 at Booth #608 and at ASTRO 2023 at Booth #3325.

Inspire Medical Systems, Inc. Announces Events at International Surgical Sleep Society and American Academy of Otolaryngology – Head and Neck Surgery Meetings

Retrieved on: 
Tuesday, September 26, 2023
Inspiration, BS, American Academy of Otolaryngology–Head and Neck Surgery, American Academy, ISSS, OSA, Down syndrome, Organization, Otorhinolaryngology, Insomnia, Patient, Westin Hotels & Resorts, Physician, MCC, BMI, Sleep, Obstructive sleep apnea, NYSE, Pharmaceutical industry, Medical imaging, MD

MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today key events at the International Surgical Sleep Society (ISSS) and American Academy of Otolaryngology (AAO-HNSF) meetings in Nashville, TN, September 29 through October 4.

Key Points: 
  • MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today key events at the International Surgical Sleep Society (ISSS) and American Academy of Otolaryngology (AAO-HNSF) meetings in Nashville, TN, September 29 through October 4.
  • “We look forward to participating in ISSS and AAO-HNSF to highlight our Inspire technology platform and share clinical data demonstrating the real-world efficacy of our therapy,” said Tim Herbert, President and CEO.
  • In the scientific sessions, Inspire will be featured throughout the meetings in panel discussions, oral abstracts, and posters presented by leading otolaryngologists and sleep surgeons.
  • October 1, 1:00 pm CT in MCC 207CD
    ADHERE registry update: Relationship of insomnia symptoms and outcomes after hypoglossal nerve stimulation.

Single-use Rhinolaryngoscope Now Distributed Exclusively by Olympus

Retrieved on: 
Monday, September 18, 2023
Contraindication, Injection, ENT, American Academy of Otolaryngology–Head and Neck Surgery, Society, Bleeding, Use, AAO, Senior, ARS, Workflow, Olympus, American Academy, Perforation, Olympus Corporation, Endoscopy, Sale, Congress, Patient, Physician, Nursing, Annual general meeting, Diagnosis, SOHN, Pharmaceutical industry, Medical imaging

WESTBOROUGH, Mass., Sept. 18, 2023 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today the launch of the Vathin E-SteriScope™ single-use flexible video rhinolaryngoscope for use in diagnostic and therapeutic otorhinolaryngological procedures. The E-SteriScope single-use flexible video rhinolaryngoscope is manufactured by Hunan Vathin Medical Instrument Co., Ltd., and distributed exclusively by Olympus. It is now available for sale in the U.S., with availability in Europe, Middle East and Africa anticipated later this year.

Key Points: 
  • The E-SteriScope single-use flexible video rhinolaryngoscope is manufactured by Hunan Vathin Medical Instrument Co., Ltd., and distributed exclusively by Olympus.
  • As a leader in endoscopy, Olympus is committed to offering a comprehensive endoscopy portfolio that includes a full range of access, visualization, and therapeutic ENT endoscopy solutions.
  • "We are very excited to launch this single-use rhinolaryngoscope as a complement to the full Olympus ENT portfolio," said Gabriel McHugh, Senior Vice President for Therapeutic Solutions at Olympus Corporation.
  • For more information about the E-SteriScope single-use flexible video rhinolaryngoscope, visit the Olympus America website: medical.olympusamerica.com/products/e-steriscope

ENT and Allergy Associates, LLP Welcomes Otolaryngologist Maheer Masood, M.D.

Retrieved on: 
Friday, September 15, 2023
LLP, American Academy of Otolaryngology–Head and Neck Surgery, University, ENG, ABR, University of Kansas Health System, Research, Anatomical pathology, American Academy of Facial Plastic and Reconstructive Surgery, Patient, Physician, Gold, Hearing, Health, Auburndale, Hospital, Nursing, Genetics, Otorhinolaryngology, Flushing, Electronystagmography

Tarrytown, New York, Sept. 15, 2023 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is pleased to announce the addition of Maheer Masood, M.D.

Key Points: 
  • Tarrytown, New York, Sept. 15, 2023 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is pleased to announce the addition of Maheer Masood, M.D.
  • Dr. Masood will be joining the group effective August 1, 2024, further enhancing the practice’s care delivery to patients in Queens County.
  • Dr. Maheer Masood is an accomplished medical professional specializing in Otolaryngology-Head and Neck Surgery.
  • The collaboration of these specialists ensures that patients will receive comprehensive and personalized care tailored to their specific needs.

Aerin Medical Announces New Positive Two-Year Results from VivAer® AERWAY Study

Retrieved on: 
Thursday, July 13, 2023
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Medical Devices, Clinical Trials, ENT, American Academy of Otolaryngology–Head and Neck Surgery, NVC, Head, McGovern Medical School, American Academy, Multimedia, Otorhinolaryngology, Nose, Network congestion, Patient, Physician, Randomized controlled trial, Steroid, NAO, Ear, Safety, Pharmaceutical industry

Results featured in Laryngoscope Investigative Otolaryngology showed a significant and long-term improvement in NAO symptom burden.

Key Points: 
  • Results featured in Laryngoscope Investigative Otolaryngology showed a significant and long-term improvement in NAO symptom burden.
  • A non-invasive technology developed by Aerin Medical Inc., VivAer uses patented, temperature-controlled radiofrequency energy to provide long-term relief from nasal obstruction.
  • The AERWAY study, a prospective, multi-center trial, followed patients after a single treatment session with VivAer and collected two-year outcomes for 91 patients.
  • “The positive two-year outcomes from the AERWAY trial build upon published VivAer clinical results, including superior symptom improvements in a randomized controlled trial and a four-year study showing long-term durability of a single VivAer treatment,” said Matt Brokaw, CEO of Aerin Medical.

NCCN Debuts Roadmap for Improving Thyroid Cancer Care in Low- and Middle-Income Countries on World Stage

Retrieved on: 
Wednesday, June 14, 2023
FEBS, World Congress of Universal Documentation, Thyroid, Framework, FACE, American Academy of Otolaryngology–Head and Neck Surgery, Survival, Cancer, Research, Journal of the National Comprehensive Cancer Network, Dana–Farber Cancer Institute, Harvard Medical School, NCCN, Investment, Regius Professor of Medicine and Therapeutics, Translation, Pain management, Palliative care, FACS, Dana, Thyroid cancer, Breast cancer, Risk management, Medical device, Core, MD

PLYMOUTH MEETING, Pa. and LONDON, June 14, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London. During the event, NCCN Senior Vice President and Chief Medical Officer, Wui-Jin Koh, MD, will present on NCCN's ongoing global work to define and advance high-quality, high-value, patient-centered cancer care. As part of that work, the non-profit alliance of leading cancer centers recently published the new NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™) for Thyroid Carcinoma, available free-of-charge at NCCN.org/global. The new resource will debut in front of more than 1,000 cancer care providers from across the globe on June 17, 2023.

Key Points: 
  • NCCN Framework for Resource Stratification of the NCCN Guidelines (NCCN Framework™) for Thyroid Carcinoma to be presented at upcoming World Congress on Thyroid Cancer in London, UK.
  • PLYMOUTH MEETING, Pa. and LONDON, June 14, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London.
  • NCCN Framework™ exists for numerous cancer types—covering more than 80 percent of cancer diagnoses—plus supportive care topics such as pain management, palliative care, and breast cancer prevention and detection.
  • The NCCN Framework™ for Thyroid Carcinoma is the first new cancer type to be added to this library in recent years.

NCCN Debuts Roadmap for Improving Thyroid Cancer Care in Low- and Middle-Income Countries on World Stage

Retrieved on: 
Wednesday, June 14, 2023
FEBS, World Congress of Universal Documentation, Thyroid, Framework, FACE, American Academy of Otolaryngology–Head and Neck Surgery, Survival, Cancer, Research, Journal of the National Comprehensive Cancer Network, Dana–Farber Cancer Institute, Harvard Medical School, NCCN, Investment, Regius Professor of Medicine and Therapeutics, Translation, Pain management, Palliative care, FACS, Dana, Thyroid cancer, Breast cancer, Risk management, Medical device, Core, MD

PLYMOUTH MEETING, Pa. and LONDON, June 14, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London. During the event, NCCN Senior Vice President and Chief Medical Officer, Wui-Jin Koh, MD, will present on NCCN's ongoing global work to define and advance high-quality, high-value, patient-centered cancer care. As part of that work, the non-profit alliance of leading cancer centers recently published the new NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™) for Thyroid Carcinoma, available free-of-charge at NCCN.org/global. The new resource will debut in front of more than 1,000 cancer care providers from across the globe on June 17, 2023.

Key Points: 
  • NCCN Framework for Resource Stratification of the NCCN Guidelines (NCCN Framework™) for Thyroid Carcinoma to be presented at upcoming World Congress on Thyroid Cancer in London, UK.
  • PLYMOUTH MEETING, Pa. and LONDON, June 14, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London.
  • NCCN Framework™ exists for numerous cancer types—covering more than 80 percent of cancer diagnoses—plus supportive care topics such as pain management, palliative care, and breast cancer prevention and detection.
  • The NCCN Framework™ for Thyroid Carcinoma is the first new cancer type to be added to this library in recent years.

LM Medical NYC - (Facial Plastic Surgery and Dermatology Specialists) Physicians are Selected as a Castle Connolly 2023 Top Doctors®

Retrieved on: 
Tuesday, May 16, 2023
Yale New Haven Hospital, Fifth Avenue, American Academy of Otolaryngology–Head and Neck Surgery, Education, Skin care, Physician, Castle Connolly Medical, American Academy, Drexel University College of Medicine, Private practice, SUNY Downstate Medical Center, Book, Ivy League, Patient, Mount Sinai Hospital, Brown University, Icahn School of Medicine at Mount Sinai, Castle, Medical degree, JAMA Facial Plastic Surgery, Dentistry, Dermatology, Biology, Medicine

NEW YORK, May 16, 2023 /PRNewswire-PRWeb/ -- For patients seeking non-surgical medical treatment for dermatological needs or wanting to explore cosmetic surgery, LM Medical NYC offers the best of both worlds. As founders of the practice, Dr. Lesley Rabach, facial plastic surgeon, and Dr. Morgan Rabach, a dermatologist, provide the highest-quality medical, surgical and cosmetic care for patients. They are both proud to be featured as "Top Doctors" for 2023 by Castle Connolly in their medical fields. Physicians who receive this impressive award are among the very best in their specialties. The education, training, hospital appointments and disciplinary history of Dr. Lesley Rabach and Dr. Morgan Rabach were rigorously screened by the Castle Connolly physician-led research team. Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com, as well as in a wide variety of partner publications, magazines and affiliate websites. The doctors who are listed in their books and directories were nominated by peers and put through an extensive evaluation process.

Key Points: 
  • NEW YORK, May 16, 2023 /PRNewswire-PRWeb/ -- For patients seeking non-surgical medical treatment for dermatological needs or wanting to explore cosmetic surgery, LM Medical NYC offers the best of both worlds.
  • They are both proud to be featured as "Top Doctors" for 2023 by Castle Connolly in their medical fields.
  • At LM Medical NYC, patients receive the benefit of access to two top physicians in their respective medical fields, all at one state-of-the-art facility.
  • LM Medical NYC has created a comfortable, upscale atmosphere, providing many services, ranging from the latest in clinical dermatology treatments to non-invasive cosmetic injections and youthful makeovers with plastic surgery.

Renowned NYC Otolaryngologist Dr. Gregory Levitin Receives Castle Connolly's 2023 Top Doctor® Award

Retrieved on: 
Monday, May 8, 2023
New York Eye and Ear Infirmary, Ear, Birthmark, American Academy of Otolaryngology–Head and Neck Surgery, Glomus tumor, Castle Connolly Medical, American Academy, Hemangioma, Microcystic lymphatic malformation, Snoring, Nose, Suite, Sinusitis, MD, Patient, Physician, Cavernous venous malformation, Allergy, FACS, Columbus Circle, Medical device, Dentistry, Nightclub, Otorhinolaryngology

NEW YORK, May 8, 2023 /PRNewswire-PRWeb/ -- Dr. Gregory Levitin has been selected as a 2023 Top Doctor® by Castle Connolly. First selected in 2018, he has continued to earn this impressive award for his expertise in Otolaryngology. For patients seeking the best care, Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com, as well as in a wide variety of partner publications, magazines and affiliate websites. After a thorough and rigorous vetting process, around 5% of the nation's licensed physicians are selected as Castle Connolly Top Doctor for their specialty.

Key Points: 
  • NEW YORK, May 8, 2023 /PRNewswire-PRWeb/ -- Dr. Gregory Levitin has been selected as a 2023 Top Doctor® by Castle Connolly.
  • First selected in 2018, he has continued to earn this impressive award for his expertise in Otolaryngology.
  • "It is always such an honor to be recognized by my peers for this award, and I consider it a significant professional accomplishment," says Dr. Gregory Levitin.
  • Dr. Gregory Levitin, MD, FACS is a board-certified otolaryngologist-head and neck surgeon and fellow of the American Academy of Otolaryngology (AAO-HNS).